Patient Support

Enroll eligible patients and learn more about a range of access resources and support services

For reimbursement support, contact R-Pharm US Access and Support in one of the following ways:

Call the Support Center at 1-855-991-7277, 8 AM to 8 PM ET, Monday through Friday

Fax the Support Center at 1-877-541-7813

Download and complete the forms as directed below:

R-Pharm US Access and Support enrollment form

Fill out this form with the help of your doctor or nurse to enroll in the R-Pharm US Access and Support program. This program offers helpful access and support resources. It can help review what benefits are covered under your plan for R-Pharm US medicines. It can also assist with the cost of your medicine if you have no active insurance.

R-Pharm US Access and Support patient authorization form

Fill out this form to allow the R-Pharm US Access and Support program to provide you with services and assistance. This form should be used only if you filled out an R-Pharm US Access and Support enrollment form but did not sign it.

The information provided is intended for use by individuals involved with reimbursement support.

The accurate completion of reimbursement or coverage-related documentation is the responsibility of the healthcare provider and patient. R-Pharm US and its agents make no guarantee regarding reimbursement for any service or item.

Indications and Important Safety Informationexpand

Important Safety Information

IXEMPRA is contraindicated in patients:


Toxicity in patients with hepatic impairment

Peripheral neuropathy


Hypersensitivity reactions

Cardiac adverse reactions


Alcohol Content


Adverse reactions


Combination with capecitabine

Cremophor is a registered trademark of BASF AG.
AST = aspartate aminotransferase; ALT = alanine aminotransferase; ULN = upper limit of normal; CTC = common terminology criteria.


IXEMPRA® (ixabepilone) is indicated for treatment in combination with capecitabine for patients with metastatic or locally advanced breast cancer resistant to treatment with an anthracycline and a taxane, or whose cancer is taxane resistant and for whom further anthracycline therapy is contraindicated.

IXEMPRA is indicated for treatment as a single agent for patients with metastatic or locally advanced breast cancer after failure of an anthracyclines, taxanes, and capecitabine.

Please see US Full Prescribing Information, including boxed WARNING regarding hepatic impairment.


Medical information

For product information or to report an adverse reaction, please call 1-844-586-8953 or e mail

This site is intended for US healthcare professionals.

The R-Pharm US Access and Support logo is a trademark and IXEMPRA® is a registered trademark of R-Pharm US Operating LLC, a wholly-owned subsidiary of R-Pharm US LLC.

© 2024, R-PHARM US. All rights reserved. IXE-00096-02   08/16